TRAINING COURSE
The broad spectrum of HPV associated diseases:
from science to practice
Sunday, May 8, 2011

The training course is designed to provide summaries of the most relevant knowledge on HPV infection and associated diseases with the aim of assisting physicians and educators in their practice. The topics cover a broad range from basic science fundamentals to emerging topics on HPV associated diseases in various locations, as well as the clinical uses of screening technologies, prophylactic HPV vaccines and management issues. Speakers will present only accepted evidence-based scientific information that has been published in the peer-reviewed medical literature.

Sunday, May 8

TC1 - HPV infection and associated diseases in the lower genital tract (cervix – vagina - vulva)

8:15 – 10:00

TC1-1 Basic research and fundamentals: state of the art
Chair: X. Bosch, J. Doorbar

- Pathogenesis and molecular biology
- Burden of HPV associated precancers and cancers
- Epidemiology of HPV infection
- Natural history revisited: age specific relationship and implications for clinical practice
- Chromosomal profiling of high-grade CIN arising from prevalent versus incident hrHPV infections
- Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 10:30</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>10:30 – 12:30</td>
<td><strong>TC1-2 Screening and vaccination – current knowledge and perspectives</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: J. Cuzick, J. Schiller</td>
</tr>
<tr>
<td></td>
<td><strong>Auditorio I</strong></td>
</tr>
<tr>
<td></td>
<td>• Cytology based screening</td>
</tr>
<tr>
<td></td>
<td>A. Herbert UK</td>
</tr>
<tr>
<td></td>
<td>• The clinical value of molecular testing in primary screening</td>
</tr>
<tr>
<td></td>
<td>T. Wright USA</td>
</tr>
<tr>
<td></td>
<td>• Implementation of guidelines for cervical cancer screening</td>
</tr>
<tr>
<td></td>
<td>A. Anttila Finland</td>
</tr>
<tr>
<td></td>
<td>• Prophylactic vaccines update</td>
</tr>
<tr>
<td></td>
<td>J. Schiller USA</td>
</tr>
<tr>
<td></td>
<td>• Vaccination programs: current experience and improvements</td>
</tr>
<tr>
<td></td>
<td>P. L. Lopalco Sweden</td>
</tr>
<tr>
<td></td>
<td>• Integrating vaccination and screening</td>
</tr>
<tr>
<td></td>
<td>M. Saraiya USA</td>
</tr>
<tr>
<td></td>
<td>• Discussion</td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td><strong>TC1-3 Management procedures of cervical HPV associated diseases</strong></td>
</tr>
<tr>
<td></td>
<td>– the standards revisited</td>
</tr>
<tr>
<td></td>
<td>– accuracy and limitation</td>
</tr>
<tr>
<td></td>
<td>Chair: T. Cox, M. Stoler</td>
</tr>
<tr>
<td></td>
<td><strong>Auditorio I</strong></td>
</tr>
<tr>
<td></td>
<td>• Performance of colposcopy</td>
</tr>
<tr>
<td></td>
<td>R. Pretorius USA</td>
</tr>
<tr>
<td></td>
<td>• The role of HPV testing for management of abnormal Pap</td>
</tr>
<tr>
<td></td>
<td>J. Roelens Belgium</td>
</tr>
<tr>
<td></td>
<td>• New evidences for an accurate follow-up</td>
</tr>
<tr>
<td></td>
<td>T. Cox USA</td>
</tr>
<tr>
<td></td>
<td>• How to treat safely high grade CIN</td>
</tr>
<tr>
<td></td>
<td>W. Prendiville Ireland</td>
</tr>
<tr>
<td></td>
<td>• Impact of HPV vaccines on disease and management</td>
</tr>
<tr>
<td></td>
<td>E. Joura Austria</td>
</tr>
<tr>
<td></td>
<td>• Discussion</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td><strong>Coffee break</strong></td>
</tr>
</tbody>
</table>
16:00 – 17:30 TC2 - HPV related neoplasia and cancer in anus, external genitalia and head & neck – facts and figures  
Chair: A. Giuliano, H. Mehanna

- Vulvar HPV related lesions: current knowledge  
  M. Sideri  
  Italy

- Anal neoplasia: epidemiology, diagnostics and prevention  
  J. Palefsky  
  USA

- Penile HPV associated diseases: what the clinician should know  
  A. Giuliano  
  USA

- The burden of head & neck HPV related cancers and the potential impact of HPV vaccines  
  M. Gillison  
  USA

- Head and neck cancer: the significance of HPV infection and treatment issues  
  H. Mehanna  
  UK

- Discussion

Sunday, May 8

10:30 – 12:30 FC1 - Epidemiology 1  
Chair: K. Syrjänen, A. Morais, F. Borruto

- HPV incident – HPV infection in older women: are they important?  
  D. Harper  
  USA

- Multiple versus single high risk HPV infection in young male and female STI-clinic attendees in The Netherlands  
  R. Vriend  
  The Netherlands

- The prevalence of human papillomavirus (HPV) infection among Korean pregnant women and transmission rate of HPVs to their infants  
  T. J. Kim  
  Korea

- The distribution of high-risk human papillomavirus genotype in high-grade cervical intraepithelial neoplasia of Korean women  
  Y.T. Kim  
  Korea

- Prevalence and risk factors for HPV infection types 16/18/45 in a French cohort of 2 166 women aged 14-23  
  A. Baudu  
  France

- Study of prevalence of HPV in women with negative cytology  
  L. Martins  
  Portugal

- Cervical HPV infection in 18 years old Italian girls  
  M. Sideri  
  Italy
• Occurrence and dynamics of HPV coinfections among Montreal university students
  M. Smith  Canada

• Relationship between cytology, histology and genotyping
  J. Nogueira  Portugal

• Human papillomavirus prevalence and genotyping among young female university students from a central area of Brazil
  V. Saddi  Brazil

• Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study
  R. Konno  Japan

• HPV type distribution in a cohort of 856 French women with atypical squamous cells of undetermined significance (ASCUS) cervical smears
  H. Marret  France

Sunday, May 8

14:00 – 15:30  FC2 - Epidemiology 2  Room 5A
  Chair : M. Steben, K. Irwin, P. Sparen

• The epidemiological burden of HPV-related cancers in men in Europe: a comparison to women
  S. Syrjänen  Finland

• A multi-center study of HPV16 & 18 prevalence in women ≥ 30 years of age using the Cervista® HPV 16/18 test
  M. Olson  USA

• HPV DNA/mRNA testing and smoking as a risk factor in predicting high grade cervical disease in women presenting with low grade cervical lesions
  C. White  Ireland

• HPV DNA presence and HPV genotypes as prognostic factors in cervical cancers
  I. H. Lee  Korea

• Prognosis of cervical cancer among immigrant and Swedish born women, during 1960 to 2005
  F. Azerkan  Sweden

• Infection with high-risk HPV genotypes in women undergoing in vitro fertilization in Slovenia
  N. Jancar  Slovenia

• HPV in vulvar cancer – Can its presence be used as a prognostic factor?
  S. Johann  Switzerland

• Risk factors for pre-cervical cancer in HIV-positive pregnant women
  C. Rijo  Portugal
Sunday, May 8
16:00 – 17:30  **FC3 - Cytology and screening**
Chair: H. Ikenberg, H. Kaufmann

- Attendance to screening and risk of cervical cancer among immigrants in Sweden, during 1993 to 2005  P. Sparen  Sweden
- The efficacy of liquid-based cytology in public screening for cervical cancer in Southern Jutland  J. Hariri  Denmark
- Improving strategies for cervical cancer prevention: the impact of SurePath liquid-based cytology in Brazilian remote rural areas. Preliminary results of RODEO study.  A. Longatto-Filho  Brazil

- Raman and FTIR spectroscopy, new technologies for cervical cancer screening and HPV testing  F. Lyng  Ireland

---

Sunday, May 8
10:30 – 12:30  **FC4 - HPV testing**
Chair: P. Halfon, C. Mougin

- Value of HPV-DNA test in women with cytological diagnosis of atypical glandular cells (AGC) – a cross-sectional study  L. C. Zeferino  Brazil
- L1 region sequencing to overcome HPV genotyping failure by a line probe assay: analysis of 856 ASCUS cervical smears from French women  C. Gaudy-Graffin  France
- HPV mRNA testing – long-term follow-up of 20,000 women in Norway  S. Sorbye  Norway
- HPV mRNA and immunocytochemistry for high grade cervical disease detection in liquid-based cytology specimens  E. Dixon  USA
- HPV-mRNA detection in the follow-up of patients with HPV infections  M. Rongioletti  Italy
- HPV E6/E7 mRNA and HPV DNA testing in post colposcopic treatment surveillance of cervical intraepithelial neoplasia  C. Martin  Ireland
- Evidence of PGMY-PCR competition and bias in the detection of HPV DNA in an ASC-US population  J. King  USA
• Sensitivity and specificity of the Cervista® HR HPV test as compared to Hybrid Capture® 2 for women 30 years and older
  S. Day USA

• Human papillomavirus-type specific risk for progression of cervical intraepithelial neoplasia
  M. Hosaka Japan

• Detection of oncogenic human papillomavirus (HPV) in anal specimens using Hybrid Capture 2: comparing collection in ThinPrep or STM media
  I. Nazarenko USA

• Comparison of the Cervista® HPV assays and HPV 4 ace for the detection of HPV 16/18 in Hybrid Capture 2 positive media
  KJ. Min Korea

Sunday May, 8

FC5 - HPV testing methods
14:00 – 16:15
  Chair: P. Snijders, JL Prétet

• European HPV DNA test External Quality Assurance Scheme (EHEQAS)
  P. Neophytou Cyprus

• Self-sampling for careHPV DNA testing: experience from three continents
  J. Jeronimo USA

• Comparison of a new automated multiplex RealTime high risk HPV assay with Hybrid Capture 2 in a large German routine laboratory
  C. Noppen Switzerland

• Analytical testing of new HPV genotyping technologies, digene© LG, RH and PS systems
  J. M. Godinez Spain

• Verification of the QIAsymphony DSP AXpH DNA kit as fully automated sample preparation for PreservCyt® specimens
  M. Sprenger-Haussels Germany

• The cobas® 4800 HPV test for high risk HPV DNA detection
  JL. Prétet France

• QIAGEN LiquiChip and Linear Array assays in a multicenter study of a population of ASCUS plus and HC2 positive patients referred for colposcopy : the 3M study (Milan, Marseilles, and Madrid)
  P. Halfon France

• Clinical validation of cobas 4800 HPV test in cervical cancer screening in Catalonia
  B. Lloveras Spain

• Optimisation of a real-time PCR for HPV DNA detection & Lipa genotyping using SPF10 primers
  I. Micalessi Belgium
• Comparison of the Papillocheck assay with the digene® HC2 HPV DNA assay for the detection of 13 HR-HPV in cervical and anal specimens  
  M. N. Didelot  France

• Effect of different extraction methods and a urine conservation medium on the detection and recovery of HPV and human DNA in urine  
  A. Vorsters  Belgium

• Vaginal self-sampling: preferences of women  
  R. Bekkers  The Netherlands

• Evaluation of a new self-sampling device for HPV-testing  
  L. Darlin  Sweden

• Analytical and functional analyses of an automated pan-HPV ISH assay for cervical biopsy tissue  
  W. Zhang  USA

• HPV genotyping on SurePath™ preservative used for pre-fixation of cone biopsies  
  H. Pedersen  Denmark

Sunday May, 8

16:15 – 17:30  FC6 - Molecular markers  Room 5B
Chair:  P. Hillemanns, F. Mota

• ProEx™ C reliably distinguishes moderate cervical dysplasia  
  T. Morgan  USA

• Differential methylation controls HPV16 gene expression during epithelial differentiation and neoplastic transformation  
  S. Vinokurova  Germany

• The effect of HPV 16/18 E6 on TERT promoter methylation in cervical cancer cells  
  L. H. Wei  China

• Expression of the p16ink4a, severity of cervical intraepithelial neoplasia and high-risk human papillomavirus infection: on-going study.  
  G. Perrini  Italy

• Loss of RKIP expression is associated with malignant progression in cervical cancer  
  O. Martinho  Portugal

• Co-expression of P63, Ki-7, p16, and human papillomavirus (HCII) in early cervical neoplasia  
  M. Guillaud  Canada

• Monitoring progression of uterine cervical epithelial lesion through 3q26 amplification FISH test  
  A. Verri  Italy
Sunday, May 8

EUROGIN – WACC SESSION
Programs, knowledge, awareness and information
Auditorio III/IV

Chair: D. Harper, M. Pitts, A. Szarewski

- Cervical cancer prevention in Russia
  V. Prilepskaya Russia

- Fighting cervical cancer in rural India: building a "grassroots infrastructure" with Community Health Workers (CHWS)
  S. Krishnan USA

- HPV vaccination in Czech Republic
  T. Fait Czech Republic

- Developing resources to support primary care health professionals in cervical screening and HPV: preliminary results from Athens
  L. McSherry Ireland

- Men and HPV: what they know and what they need to know
  M. Pitts Australia

- Women’s views of HPV vaccination in Ireland: findings from a national population survey
  M. O’Connor Ireland

- HPV vaccination: knowledge, practice and behavioural intentions about prevention of cervical cancer and STD in French adolescents
  Y. Leocmach France

- Does university students’ knowledge influence HPV vaccination? Implications in health care programs
  D. Ramada Portugal

- Relation between vaccination status and teens’ knowledge on HPV infection and vaccination
  F. Sopracordevole Italy

- Predictors of HPV vaccine acceptability in Japanese mothers: maximizing the public health impact of HPV vaccination in Japan
  S. Hanley Japan

- Pattern of use of HPV vaccine and adherence to vaccination schedule among individuals excluded from the Portuguese vaccination program
  C. Torre Portugal

- Safety, feasibility and acceptability of via and immediate treatment with cryotherapy in rural Laos
  K. Phongsavan Sweden

- Inuit women’s acceptance and preference of HPV self-sampling in Nunavik, Quebec
  P. Brassard Canada
• Acceptability of HPV self-sampling for cervical cancer screening in a low resource country  A. Berner  Switzerland

• Long-term worries in women with low-grade abnormal cytology managed by alternative policies at colposcopy: the TOMBOLA trial  L. Sharp  Ireland

• From good intentions to actual uptake: a comparison of predictors of HPV vaccination in college women  Z. Rosberger  Canada

• State of the science: uptake of the HPV vaccine among young women and girls in the US with comparisons to other developed and developing countries  S. Sheinfeld Gorin  USA

• High uptake HPV vaccination rates for adolescent girls after regional governmental funding in Shiki city, Japan  Y. Hayashi  Japan
Plenary Sessions (PS)

Plenary Sessions will include keynote lectures providing a broad overview of the essential issues of cervical cancer prevention by the most prominent experts in their respective field.

Clinical (translational) sessions (CS): from basic science to clinical practice

Debates on controversial issues

The clinical sessions are designed to provide educational strategies and skill-building learning experiences and update of expertise for participants. The clinical sessions should enable participants to integrate in their everyday practice the basic and advanced principles of colposcopy as well as diagnosis and management of cervico-vaginal and vulvar diseases.

Concurrent Scientific Sessions (SS)

These concurrent sessions feature presentations of selected abstracts on new findings covering a broad range of topics related to HPV research, cancer screening prevention and management of patients with HPV-associated diseases. Each presentation should not exceed 8 minutes.

Monday, May 9
PLENARY SESSION
8:00 – 9:30  PS1- Cervical cancer screening – role of molecular testing
Chair: T. Cox, C. Meijer

- Optimal screening intervals
- Screening strategies for women 30 years and older
- Current knowledge on screening of women less than 30
- Management of cytonegative / HPV positive women
- Exiting women from screening
- Cervical cancer screening as a post-vaccination surveillance activity

Auditorio I

T. Cox  USA
J. Dillner  Sweden
P. Sasieni  UK
P. Castle  USA
W. Kinney  USA
E. Franco  Canada

Monday, May 9
PLENARY SESSION
9:30 – 11:00  PS2 - HPV vaccination – current knowledge and the road to the future
Chair: J. Schiller, M. Stanley

- Vaccine benefits following sexual debut (catch-up/adult)
- New evidence for vaccination of males

Auditorio I

M. Stanley  UK
A. Giuliano  USA
- Real life impact of HPV vaccine at population level
  - The UK experience
    - D. Salisbury  UK
  - The Australian experience
    - J. Brotherton  Australia
- Long-term follow-up: the Nordic experience (bivalent vaccine)
  - M. Lehtinen  Finland
- An evaluation of the long-term effectiveness, immunogenicity and safety of the quadrivalent vaccine in previously vaccinated women
  - S. Krüger Kjaer  Denmark
- HPV vaccination efficacy with less than 3 doses
  - A. Kreimer  USA

---

**Monday, May 9**
**MAIN SCIENTIFIC SESSION**

**14:00 – 15:30**  
**MSS1 - Penile HPV related diseases revisited**  
**Chair: C. Lacey, A. Giuliano**  
**Auditorio I**

- The burden of HPV associated penile cancer
  - K. d'Hauwers  The Netherlands
- Current knowledge on epidemiology and natural history
  - C. Munk  Denmark
- Male sexual behaviour – a risk factor for cervical cancer?
  - X. Bosch  Spain
- The global spectrum of HPV related diseases in males
  - C. Lacey  UK
- Management of penile HPV associated lesions
  - G. Gross  Germany
- HPV vaccination: what have we learned from the clinical trials?
  - A. Giuliano  USA
- Impact of male circumcision on women with HPV genital disease
  - P. Gravitt  USA

---

**Monday, May 9**
**MAIN SCIENTIFIC SESSION**

**15:30 – 17:00**  
**MSS2 - Anal HPV associated diseases and cancer: state of the art**  
**Chair: J. Palefsky, N. Wentzensen**  
**Auditorio I**

- The burden of the diseases and natural history
  - C. Munk  Denmark
- Factors influencing HPV dysplasia and anal cancer following HPV infection
  - N. Wentzensen  USA
• Diagnostic methods and clinical features  S. Goldstone  USA
• Who should be screened? Is screening an effective tool?  L. Abramowitz  France
• Current management of AIN3 and cancer  S. Goldstone  USA
• Quadrivalent HPV vaccine efficacy against high-grade anal intraepithelial neoplasia in men having sex with men  J. Palefsky  USA

Monday, May 9
CONCURRENT SCIENTIFIC SESSION
14:00 – 15:30  SS1 – New generation of HPV assays for clinical practice  Auditorio II
Chair: J. Cuzick, A. Pista

- How to manage screen cyto negative HPV positive women  G. Ronco  Italy
- Primary screening validation of the Abbott RealTime high risk HPV assay  M. Poljak  Slovenia
- Detection of high-risk HPV oncogenic mRNAs as an adjunct method for cervical cancer screening; baseline results for the Clinical Evaluation of APTIMA HPV mRNA (CLEAR) US clinical trial  T. Wright  USA
- Clinical validation of the detection of high-risk HPV oncogenic mRNAs in the triage of ASC-US diagnosis; results for the Clinical Evaluation of APTIMA HPV mRNA (CLEAR) US clinical trial  M. Stoler  USA
- Clinical performance of a new BD Viper HPV screening assay  L. Vaughan  USA
- Cellular quantification of HPV E6, E7 mRNA improves detection of high grade cervical lesions compared to HPV DNA  G. Karakitsos  Greece
- Diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: results of a 2-year prospective study  S. Tiews  Germany

Monday, May 9
CONCURRENT SCIENTIFIC SESSION
15:30 – 17:00  SS2 - The value of HPV genotyping  Auditorio II
Chair: P. Gravitt, C. Clavel

- Ecological competition of HPV types before and after mass vaccination  M. Lehtinen  Finland
- HPV genotyping based screening: what are the evidences?  J. Dillner  Sweden
- Repeat HPV testing vs. cytology triage of women following a single HR-HPV DNA test  P. Gravitt  USA
- Evaluation of the HPV16/18 triage strategy for HRHPV-positive women aged ≥30 years with NILM cytology: ATHENA baseline results  T. Wright  USA
- Age-dependent variation in HPV test performance for ≥CIN2 detection in women with ASC-US: an ATHENA trial update  M. Stoler  USA
Monday, May 9
CONCURRENT SCIENTIFIC SESSION

14:00 – 15:30 SS3 - Vaccines 1 – Current knowledge of HPV vaccine impact
Room 5A/B

Chair: C. de Oliveira, M. Steben

- Global reduction of cervical cancer with HPV vaccine: insights from the hepatitis B vaccine experience
  - B. Romanowski Canada

- Methods to monitor the impact of HPV vaccination process in high, middle and low resource countries
  - J. Brotherton Australia

- Early benefits and prevention of abnormal smears
  - Bivalent
  - Quadrivalent

- Reduction in colposcopy and clinical procedures
  - Bivalent
  - Quadrivalent

- Long-term efficacy of human papillomavirus vaccination against CIN 3 and invasive carcinoma: registry based follow up of a phase III TRIAL (FUTURE II)
  - J. Paavonen Finland

- The clinical impact of cross protection with the bivalent vaccine
  - T. Schwarz Germany

- Analysis of quadrivalent HPV vaccine efficacy against HPV 16/18 persistent infection in both men and women
  - M. Steben Canada

Monday, May 9
CONCURRENT SCIENTIFIC SESSION

15:30 – 17:00 SS4 - Vaccines 2 – HPV vaccine programs and monitoring: current status and lessons learned
Room 5A/B

Chair: S. Garland, D. Pereira da Silva

- Long-term protection of HPV bivalent vaccines
  - B. Romanowski Canada

- How to overcome barriers of vaccination in your practices
  - A. Szarewski UK

- Experience by country: Round table

- School based programs:
  - UK: surveillance of vaccine program
  - Australia
  - K. Soldan UK
  - J. Brotherton Australia
• Voluntary based initiatives:
  • USA
  • France
  • Italy
  • Portugal
  • Belgium/The Netherlands/Luxemburg
  • Nordic countries
  • Denmark

Monday, May 9
CONCURRENT SCIENTIFIC SESSION
14:00 – 15:30 SS5 - Vulvar neoplasia, cancer and mimics: what the clinicians should know
Chair: J. Bornstein, J. Martinez de Oliveira
- Burden, epidemiology and populations at risk
- Clinical features
- Management
- Role of colposcopy
- Impact of vaccination
- Discussion

Monday, May 9
CONCURRENT SCIENTIFIC SESSION
15:30 – 17:00 SS6 - New developments in cytopathology
Chair: A. Herbert, C. Lopes
- Adjunctive use of a novel HPV ISH assay significantly improves diagnostic accuracy in cervical biopsy interpretation
- Automated screening of gynecological cytology: a comparison of results
- The Italian Abruzzo study: liquid based cytology & ThinPrep imaging system vs conventional cytology & focalpoint system (ARINT Study)
- Multicyte™ ThinPrep® imaging: the Scottish experience
- A randomized trial comparing conventional cytology to liquid based cytology with computer-assistance: results of the Rhine-Saar-study
- Detection of human papillomavirus associated genomic instability in cervical FFPE biopsies
Tuesday, May 10  
PLENARY SESSION  

8:00 – 9:30  
PS3 - Can we target the adult population at high risk of cervical cancer? Consequences on screening, management and vaccination  
Chair: E. Franco, N. Broutet

- The risk heterogeneity of high-grade CIN  
  N. Wentzensen  
  USA

- Assessing inequalities over the world (access, resources, education) and potential solutions  
  N. Broutet  
  Switzerland

- Epidemiologic, genetic, behavioural factors and the male partner influence: are they important?  
  E. Franco  
  Canada

- Significance of molecular testing/markers and age of exposure to HPV  
  P. Castle  
  USA

- Specific populations at high risk of cervical cancer: should screening and vaccination be different?  
  T. Cox  
  USA

- Integrating and implementing screening and vaccination programs for high risk populations  
  L. Denny  
  South Africa

9:30 – 11:00  
PS4 - Head and neck HPV associated cancer – state of the art  
Chair: M. Gillison, S. Syrjänen

- Virological approach – meta-analysis data  
  S. Syrjänen  
  Finland

- Oral HPV infection and head and neck cancer risk  
  A. Kreimer  
  USA

- Evidence of causal association between HPV and head and neck cancer  
  M. Gillison  
  USA

- Molecular diagnostic methods and prognostic markers utility  
  P. Gravitt  
  USA

- Tumor HPV status management and survival  
  H. Mehanna  
  UK

- The potential impact of HPV vaccines  
  S. Krüger Kjaer  
  Denmark
Tuesday, May 10
MAIN SCIENTIFIC SESSION

14:15 - 15:15 MSS3 - New professional guidelines on screening and vaccination
Chair: T. Wright, M. Arbyn

- USA
  - T. Wright
- Europe
  - M. Arbyn
- FIGO
  - S. Pecorelli
- WHO
  - N. Broutet
- Providers and practices
  - M. Saraiya
- Panel discussion: do we need to update the current recommendations?

Tuesday, May 10
MAIN SCIENTIFIC SESSION

15:15 - 16:15 MSS4 - HPV screening: current programs and implementation procedures
Chair: L. Denny, H. Lawson

- Europe:
  - the Dutch program
    - C. Meijer
    - G. Ronco
  - the Italian experience
- USA
  - H. Lawson
- Developing world
  - L. Denny

Tuesday, May 10
MAIN SCIENTIFIC SESSION

16:45 – 17:45 MSS5 - Health economics of HPV related precancers and cancers – screening and prevention: priorities and opportunities
Chair: S. Kulasingam, P. Bonanni

- The respective public health impact of screening and vaccination: what the economic models tell us
  - S. Kulasingam
- What are the public health priorities in the developed world?
  - M. Jit
- Adult vaccination is it cost effective?
  - J. Bogaards
Tuesday, May 10

8:00 – 9:30

**FC7 – Head and neck**

*Auditorio II*

Chair: A. Kreimer, T. Iftner

- Age-period-birth cohort analysis of HPV associated and unassociated oral cancers in British Columbia Canada
  
  M. Rosin Canada

- Viral load, physical status, and E6/7 mRNA expression of human papillomavirus in head and neck squamous cell carcinoma
  
  M. Suzuki Japan

- Genetic variants of pre-mirna genes as a predictor of HPV16 status and survival of oropharyngeal cancer patients
  
  K. Dahlstrom USA

- Human papillomavirus infection and p16^{ink4a}/ki-67 co-expression in the head and neck squamous epithelium
  
  E. Prigge Germany

- Primary squamous cell carcinoma of the tonsils, human papillomavirus detection, typing and relation to p16^{ink4a} correlated to overall survival
  
  R. Christensen Denmark

- Oral HPV prevalence among HIV-1 infected males and females in Italy
  
  A. Del Mistro Italy

Tuesday, May, 10

9:30 – 11:00

**FC8 – Diagnosis and Management**

*Auditorio II*

Chair: M. Roy, E. Siegler

- High-risk HPV DNA in lymph nodes in cervical cancers patients
  
  J. Slama Czech Republic

- Cervical cancer in India: incidence and treatment strategies
  
  U. Chatterji India
• Finnish medical birth registry data during 1998-2009: 
  leep conisation and the risk for preterm birth
  A. Heinonen Finland

• Performance of high-risk HPV test in the surveillance
  of patients treated for high grade cervical 
  intraepithelial neoplasia.
  M. Beccati Italy

• Improved detection of high grade CIN in women 
  undergoing colposcopy using electrical
  impedance spectroscopy
  J. Tidy UK

• Peniscopic evaluation of the male partners of
  women treated for high grade cervical lesions
  C. Liverani Italy

• Introducing a new diagnostic modality into the
  standard of care
  L. Flowers USA

Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

14:15 – 15:45 SS7 – Contemporary management of CIN
Chair: W. Prendiville, E. Diakomanolis

• Risk of invasive cancer in routine clinical practice 
  following a CIN2 or CIN2/3 biopsy
  W. Kinney USA

• Current management in low-resource settings
  J. Jeronimo USA

• Random biopsy detects additional high-grade 
  cervical disease in women with normal colposcopy
  W. Huh USA

• Management controversies of CIN1
  E. Siegler Israel

• Adverse pregnancy outcomes related to treatment
  of CIN
  M. Cruickshank UK

• Post treatment efficacy data
  E. Joura Austria

• Photodynamic therapy (PDT) of cervical 
  intraepithelial neoplasia (CIN)
  P. Soergel Germany

• Training in colposcopy
  J. Cortes Spain

• The health professional as an actor for mobilizing
  the patient: the principles of public education
  D. Harper USA

Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

16:15 – 17:45 SS8– Best practices of colposcopy
Chair: J. Cortes, A. Singer, J. Cardoso Moutinho

• Controversies on the accuracy of colposcopy 
  directed biopsy
  R. Pretorius USA

• Developing strategies to improve knowledge of
  best practices
  W. Prendiville Ireland

• Towards a new IFCPC colposcopy terminology
  J. Bornstein Israel

• Pitfalls of colposcopy particularly in relation to 
  glandular disease
  S. C. Quek Singapore
Changes in colposcopy terminology: from disease recognition to pattern recognition

Case studies

M. Sideri
Italy

R. Pretorius
USA

W. Prendiville
Ireland

A. Singer
UK

M. Sideri
Italy

S. C. Quek
Singapore

Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

14:15 – 16:15 SS9 - Vaccines 3 – From clinical trials to real life settings
Auditorio III/IV

Chair: J. Paavonen, B. Romanowski

- First look at effectiveness data from a long-term extension study of Gardasil in adolescents
  D. Ferris
  USA

- Long-term follow-up (LTFU) study of HPV-type-specific disease in previously Gardasil® vaccinated women
  J. Dillner
  Sweden

- Does the bivalent vaccine for human papillomavirus 16 and 18 benefit women with cervical disease?
  S. Garland
  Australia

- Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule 2-years after vaccination
  B. Romanowski
  Canada

- The impact of quadrivalent HPV vaccine on external genital biopsies and surgical/non-surgical procedures in men
  A. Giuliano
  USA

- Disease-specific adverse events following the quadrivalent HPV vaccine (qHPVV): another spontaneous reporting bias?
  B. Soubeyrand
  France

- Surveillance of congenital anomalies in babies born to women exposed to Gardasil® during pregnancy
  K. Jensen
  Denmark

- Post-licensure safety study of quadrivalent human papillomavirus vaccine among 189,629 females
  C. Velicer
  USA

- A registry-based long-term follow-up (LTFU) study of the quadrivalent HPV (qHPV) vaccine in four Nordic countries
  M. Nygård
  Norway

- Safety of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) (qHPV) vaccine in China: a randomized, double-blind, placebo-controlled trial
  C. Zhao
  China

- A model for assessing HPV vaccination strategies. A dynamic modelling approach
  T. Westra
  The Netherlands

- A registry-based long-term follow-up study of the safety of the quadrivalent HPV (qHPV) vaccine in Scandinavia
  A. Saah
  USA
Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

16:15 – 17:45  SS10 - Screening
Chair: G. Ronco, J. Dillner

- How to evaluate emerging technologies in cervical cancer screening
- The value of self-sampling
- Age issues in HPV screening
- Hybrid Capture 2 detection of high-risk HPV is a useful screening tool for anal dysplasia
- Do women age 66 - 80 benefit from a Pap smear after age 61? The Swedish nationwide audit of cervical cancer screening
- Primary HPV testing in a Canadian population-based screening program
- HPV DNA testing as a primary screening tool for cervical cancer: analysis of 17 population-based studies from China
- Screening history preceding a diagnosis of cervical cancer in women age 65 and older
- 10 years follow up after a negative HPV test
- HPV self-sampling as an alternative strategy in non-attenders for cervical screening – a randomised controlled trial

AuditorioIII/IV

G. Ronco  Italy
D. Heideman  The Netherlands
A. Anttila  Finland
S. Goldstone  USA
B. Andrae  Sweden
D. Van Niekerk  Canada
F. H. Zhao  China
H. Dinkelspiel  USA
J. C. Boulanger  France
L. Cadman  UK

Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

17:45 – 19:00  SS11 - Epidemiology 1
Age specific HPV infection and disease
Chair: S. Krüger Kjaer, J. Borrego

- Epidemiology of HPV associated head & neck cancers
- Age-specific HPV incidence and prevalence: potential perspective for screening and vaccination
- Age related HPV cervical associated diseases, consequences for screening, management and vaccination
- Age specific occurrence of new HR HPV cervical infection in screening population
- Adolescents, young women and HPV
- Middle age women and HPV
- Menopause and HPV

AuditorioIII/IV

A. Chaturvedi  USA
E. Franco  Canada
A. Anttila  Finland
F. Carozzi  Italy
A. B. Moscicki  USA
M. H. Mayrand  Canada
P. Gravitt  USA
Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

16:15 – 17:45 SS12 - p16 in cervical and other HPV related cancer
Chair: T. Wright

- Introduction: p16 biomarker in cervical cancer diagnosis
- p16/Ki-67 dual-stained cytology in primary screening for cervical cancer and as triage tool in pap negative / HPV positive cases
- Triage of ASC-US and LSIL cytology results with p16/Ki-67 dual stain
- P16 immunohistochemistry: a potential objective biomarker standard in cervical and non-cervical histopathology

Room 5A

T. Wright USA
H. Ikenberg Germany
C. Bergeron France
M. Stoler USA

Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

17:45 – 19:00 SS13 – The emerging value of molecular markers
Chair: J.P. Bogers, M. von Knebel-Doeberitz

- Conceptual framework for evaluation of molecular markers potentially usable for cancer screening
- Combined expression of p16\(^{\text{INK4a}}\) and Ki-67 in cervical epithelial cells indicates high grade intraepithelial neoplasia and cancer
- Methylation markers as triage tool for HPV positive women
- Improved cervical cancer screening for the detection of CIN2+ disease by combining biomarker over-expression with a Pap counterstain
- Budget impact model for RNA testing with HPV OncoTect\textsuperscript{®} for high-risk HPV
- Screening for anal intraepithelial neoplasia (AIN) using HPV OncoTect increases sensitivity and specificity compared HPV DNA
- HPV genome methylation: relationship with cervical disease progression
- Detection and quantification of HPV E7 oncoproteins in cervical smears

Room 5A

J. Cuzick UK
M. von Knebel-Doeberitz Germany
D. Heideman The Netherlands
C. Whitehead USA
T. Goss USA
P. Phanuphak Thailand
L. Marongiu UK
P. Jansen-Dürr Austria

Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

14:15 – 15:45 SS14 - HPV and heterogeneity of head and neck cancers
Chair: M. Gillison

- The burden of HPV related head and neck cancer
- Comparison of molecular methods for detection of HPV in oral and oropharyngal squamous carcinoma
- HPV and clinical heterogeneity of head and neck cancer

Room 5B

H. Mehanna UK
P. Gravitt USA
M. Gillison USA
- HPV and heterogeneity of head and neck cancers at population level
  A. Chaturvedi
  USA
- HPV genomic profiling and in vitro modelling
  R. Steenbergen
  The Netherlands

**Tuesday, May 10**
**CONCURRENT SCIENTIFIC SESSION**

**16:15 – 17:45 SS15 – New trends on HPV testing and other markers**
**Chair:** T. Iftner

- HPV mRNA testing and other mRNA markers: a review
  T. Iftner
  Germany
- Potential cost-effectiveness of HPV RNA testing for ASCUS triage and primary screening in the United States
  E. Myers
  USA
- Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions
  M. Arbyn
  Belgium
- Distribution of the HPV HR types using the *digene HPV Genotyping LQ Test* in a multicenter study of a population of ASCUS plus and HC2 positive patients referred for colposcopy: the 3M study (Milan, Marseilles, and Madrid)
  P. Halfon
  France
- HPV DNA testing and cytology as predictors of histologically confirmed cervical disease: evidence from the Ludwig-McGill cohort
  M. Chevarie-Davis
  Canada
- A comparison of HPV type-specific results among women with abnormal smears
  D. Mesher
  UK
- Combined morphologic and molecular assessment of cervical cells in suspension – the slideless Pap
  B. Patterson
  USA

**Tuesday, May 10**
**Clinical Session**

**14:15 -15:45 CS1 - Clinical session 1**
**Chair:** M. Sideri, C. Marques

- HPV testing in primary screening: should organized programs be requested before implementation?
  Yes
  A. Anttila
  W. Kinney
  Finland/
  USA
  No
- CIN2: to treat or not?
  Yes
  M. Sideri
  M. Stoler
  Italy/
  USA
  No
- Moving from algorithms to risk based management: is it of value for the clinician?
  Yes
  P. Castle
  J. Dillner
  USA/
  Sweden
  No
- HPV testing: what is the preferable assay from a clinical perspective?
  J. Cuzick
  T. Wright
  UK/USA
• Accuracy of colposcopy: multiple biopsies required or not?
  Yes R. Pretorius USA/
  No W. Prendiville Ireland

Wednesday, May 11
CONCURRENT SCIENTIFIC SESSION
8:00 – 9:30 SS16 - Recent advances and gaps in research
Chair: E. Franco, P. Castle

• Unresolved questions concerning HPV infection and transmission E. Franco Canada
• Biology of transmission/infection J. Schiller USA
• Viral latency vs recurrence new infection A.B. Moscicki USA
• Molecular phenotypes of HPV genotypes T. Iftner Germany
• Role of epidemiology in the understanding of HPV transmission A. Giuliano USA
• Reservoir genital sites in HPV transmission M. Goodman USA
• Conclusion P. Castle USA

Wednesday, May 11
CONCURRENT SCIENTIFIC SESSION
9:30 – 11:00 SS17 - Epidemiology 2 - recent advances on epidemiology
Chair: S. De Sanjosé, M.H. Mayrand

• The duration of infection and clearance of HPV 6, 11, 16 and 18 in men aged 16 to 26 A. Giuliano USA
• Incidence and costs of anal, penile, vaginal and vulva cancer in Denmark J. Olsen Denmark
• Increased risk of mother to child transmission of HPV in HPV positive mothers D. Vanden Broeck Belgium
• Human papillomavirus genotype attribution in invasive cervical cancer and the usefulness of HPV 16, 18, and 45 genotyping S. de Sanjosé Spain
• HPV genotypes attribution in cervical cancers and impact on screening and vaccination: the Swedish experience J. Dillner Sweden
• Genital human papillomavirus infections in young females with or without co-infection of chlamydia trachomatis R. Vriend The Netherlands
• Estimation of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies A. Lewkowitz China
• Risk factors for HPV infection in women in Portugal – the Cleopatre Portugal study A. Pista Portugal
• The role of cofactors in progression of cervical precancerous lesions M. deVries Canada
Wednesday, May 11
CONCURRENT SCIENTIFIC SESSION
11:00 – 12:30 SS18 - Vaccines 4 - New developments in HPV vaccines and drugs
Chair: J. Schiller, P. Coursaget

- Cochrane review: prophylactic vaccination against HPV
  M. Arbyn Belgium
- L2 as a target for prophylactic vaccination
  S. Jagu USA
- Intravaginal vaccination with HPV pseudovirions
  J. Schiller USA
- Therapeutic vaccine approaches
  T. C. Wu USA
- A novel prophylactic vaccine (RG1-VLP) against a broad spectrum of mucosal and cutaneous HPV
  R. Kirnbauer Austria
- A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8 T cell immunity and regression of large, established, E7-expressing TC-1 tumors
  J. Webb Canada
- Sulindac has anti-neoplastic activity towards cervical cancer cells
  C. Spillane Ireland
- Detection of E6-AP as a potential therapeutic target in cervical specimen of HPV-infected women
  P. Hillemanns Germany

Wednesday, May 11
CONCURRENT SCIENTIFIC SESSION
12:30 – 14:00 SS19 – Advanced topics on immunology and immunization
Chair: P. Stern, B. Moscicki

- Introduction
  P. Stern UK
- Mechanisms of viral neutralization
  J. Schiller USA
- Comparison of immunogenicity of two prophylactic human papillomavirus (HPV) vaccines at month 36
  M. Einstein USA
- Local immune responses to HPV and neoplasia
  B. Moscicki USA
- Antibody response to the quadrivalent HPV vaccine: correlation of total IgG assay with pseudovirion based neutralization assay
  D. Brown USA
- Long term ex vivo monitoring of memory CD4 T helper cell responses in women immunized with Gardasil® or Cervarix®
  A. Kaufmann Germany
- Age-specific human papillomavirus antibody and concordant DNA prevalence: a global review
  S. Tiggelaar China
- Development and qualification of an automated pseudovirion-based HPV-neutralization assay
  P. Sehr Germany

Wednesday, May 11
CONCURRENT SCIENTIFIC SESSION
8:00 – 9:45 SS20 - Molecular biology and detection
Chair: M. Favre, J. Doorbar

- Gene expression profiling on cervical swabs for molecular classification of intraepithelial neoplasia
  A.S. Riteau France
- The role of chromosomal integration to induce the transforming type of HPV gene expression in cervical lesions
  A. Chaiwongkot Germany
- Antigen expression and localization from a MVA-based vector (RG3484) encoding genes for human IL-2 and modified HPV16 E6 and E7  
  
  - An E6 protein based rapid diagnostic test for cervical pre-cancer and cancer – detection of E6 oncoprotein from fixed cells  
  
  - Significance of molecular pathological examination of cervical biopsies for high risk groups with HPV associated cervical dysplasia  
  
  - High risk human papillomavirus induced expression of endothelial and inducible nitric oxide synthases in human uterine cervix  
  
  - Association of interleukin-10 gene promoter polymorphisms and gene expression in human papillomavirus cervical lesions  
  
  - Gain-of-function Wnt-independent activity of the Pygopus2 transcription factor in gynecologic cancer  
  
  - Development of a new HPV diagnostic tool based on the use of arrayed and nanoparticle-bound DNA probes

**Wednesday, May 11**  
**CONCURRENT SCIENTIFIC SESSION**

**9:45 – 11:00 SS21 - HPV/HIV natural history – new insights**  
**Chair:** P. Gravitt, J. Smith  
**Room 5A**

- Prevalence of HPV infection in HIV+ women  
  
  - Risk of anal cancer  
  
  - Role of HPV in HIV transmission  
  
  - HPV screen and treat in HIV infected women  
  
  - Potential/rational of HPV vaccine  

**Wednesday, May 11**  
**CONCURRENT SCIENTIFIC SESSION**

**11:00 – 12:30 SS22 – New insights in low resource settings**  
**Chair:** M. Kane, J. Jeronimo  
**Room 5A**

- Screening methods for developing countries  
  
  - Treatment limitation in low resource setting  
  
  - HPV infection in men  
  
  - careHPV™ Test pilot performance in rural northern Tanzania  
  
  - Implementation of HPV vaccination in low resource settings  
  
  - Cochrane review: screening in developing countries  
  
  - Cost-effectiveness analysis of Pap smear screening strategies in rural China
SS23 - HPV associated diseases and cancers in other tissues: what is the evidence?
Chair: T. Broker, K. Syrjänen

- Overview
- Skin cancer
- Lung cancer
- Oesophagus
- Laryngal papillomatosis
- Investigating the role of HPV in lung cancer: a pooled analysis
- Detection of human papillomavirus type 16 DNA but absence of expression of E5, E6 and E7 viral mRNA in colorectal cancers
- Investigation of genital HPV infection in Cypriot men and in male urogenital cancers
- Conclusion

Wednesday, May 11
CONCURRENT SCIENTIFIC SESSION

8:00 – 10:00 SS24 - HPV testing methods: an update
Chair: F. Carozzi, P. Snijders

- Evaluation of sampling methods for detection of anogenital HPV in men who have sex with men
- Human papillomavirus testing in primary cervical screening and the cut-off for Hybrid Capture 2 tests: a systematic review
- QIAsymphony AXpH sample preparation for automated conversion of PreservCyt specimens for use in the digene HC2 high-risk HPV DNA test
- Limitations of widely used high risk HPV DNA testing in patients with invasive cervical cancer
- Clinical performance of a new BD VIPER™ HPV screening assay
- Evaluation of the RealTime high risk HPV assay with simultaneous typing of HPV16 and HPV18 in women with atypical Pap smear
- Use of HPV OncoTect® for pre-squamous cell carcinoma and pre-adenocarcinoma detection and differentiation
- Clinical evaluation of the standardised GP5+/6+ EIA kit
- HPV testing with cytology triage in cervical screening: influence of revealed versus concealed HPV status
- Clinical performance of the Cervista® HPV HR assay using specimens preserved in different liquid-based cytology media
10:00 – 12:30 SS25 - Quality assessment of HPV testing
Chair: H. Cubie, C. Meijer
• External quality assessment of HPV testing  
  H. Cubie  UK
• Validation and quality assessment of HPV testing assays  
  P. Snijders  The Netherlands
• Comparative clinical performance of HPV genotyping assays: the critical issues  
  T. Iftner  Germany
• Round table
  Genotyping prevalence by country
  o Italy  F. Carozzi  Italy
  o UK  H. Cubie  UK
  o France  J. Monsonego  France
  o Germany  T. Iftner  Germany
  o The Netherlands  C. Meijer  Netherlands
  o Sweden  J. Dillner  Sweden
  o Portugal  C. Bicho  Portugal
  o Greece  A. Agorastos  Greece
  o Spain  S. De Sanjosé  Spain
• Role of national reference centers for evaluation of HPV distribution before and after vaccination  
  J. Dillner  H. Cubie  Sweden  UK

Wednesday, May 11
CONCURRENT SCIENTIFIC SESSION
8:00 – 9:30 SS26 – Management of cervical cancer: new strategies
Chair: S. Dexeus, M. Roy
• Conservative management (uterus and ovary) of micro-invasive and invasive adenocarcinoma: are the oncological limits similar to squamous cell carcinoma?  
  M. Roy  Canada
• Should the neoadjuvant treatment (chemotherapy or chemoradiotherapy) of advanced stage adenocarcinoma be similar to squamous cell carcinoma?  
  P. Madeira  Portugal
• Does adenocarcinoma of the uterine cervix should be treated similarly to squamous cell carcinoma?  
  S. Dexeus  Spain
• Does the incidence of adenocarcinoma increase?  
  K. Syrjänen  Finland
• Unusual endocervical adenocarcinomas: HPV detection and immunohistochemical analysis  
  K. Park  USA
Wednesday, May 11

CS2 - Clinical session 2
9:30 – 11:00
Chair: A.B. Moscicki, A. Petiz

• Head and neck cancers: is HPV of significant interest?
  Yes  M. Gillison  USA
  No  A. Chaturvedi  USA

• The best management of cytonegative HPV positive women
  G Ronco  Italy
  A. Anttila  Finland

• Verification bias: does it matter?
  Yes  E. Franco  Canada
  No  J. Cuzick  UK

• Treatment of CIN causes premature delivery
  Yes  M. Arbyn  Belgium
  No  M. Cruickshank  UK

• Screening of anal cancer
  Yes  S. Goldstone  USA
  No  M. Brisson  Canada

Wednesday, May 11
Clinical Session

CS3 - Clinical session 3
11:00 – 12:30
Chair: J. Paavonen, A. F. Jorge

• HPV vaccine for high risk populations: is it of a public health value?
  Yes  C. Lacey  UK
  No  M. Steben  Canada

• HPV vaccination of males: yes or no?
  Yes  A. Giuliano  USA
  No  M. Jit  UK

• HPV vaccination for adult women: yes or no?
  Yes  J. Bogaards  The Netherlands
  No  H. Lawson  USA

• Could antibodies be considered as an indicator of efficacy
  Yes  P. Stern  UK
  No  S. Garland  Australia
### Wednesday, May 11

**12:30 – 14:00**  
**FC9 – New insights on human papillomavirus infection and related diseases in HIV patients**  
**Room 5C**

**Chair: L. Abramowitz, J. Smith, J. Fonseca Moutinho**

- High risk HPV types in women with abnormal cervical cytology in a South African population with a high prevalence of HIV  
  - K. Richter  
  - South Africa
- Results of 1206 HIV–infected patients screened for anal lesions (condylomas, dysplasia and cancer).  
  - L. Abramowitz  
  - France
- Pilot study of HPV prevalence and cervical epithelial neoplasia among HIV-infected women in Yunnan province, China  
  - HY. Zhang  
  - China
- Relation between anal and cervical HPV screening and cytology: study in HIV neg women  
  - W. Tjalma  
  - Belgium
- Carcinogenic and incidental HPV types in HIV positive vs. negative South African women with cervical pre-neoplasia  
  - M. van Aardt  
  - South Africa
- Cervical and anal Pap smear screening among drug users living with HIV in Miami, Florida.  
  - I. Rosa-Cunha  
  - USA
SPECIALIZED TRAINING COURSES

Sunday, May 8

14:00 – 17:30  SPC1 - Vaccinology Training Course
Chair: P. Bonanni

- All about vaccination and vaccines specificities
- Basics of immunology
- Risks of vaccines and monitoring vaccines safety
- Detecting and assessing adverse events following immunisation: how to distinguish cause and coincidence
- How to improve participation
- Implementation of vaccine programs
- Social, ethical and communication issues

Room 5C

P. Bonanni  Italy
P. Stern  UK
S. Garland  Australia
P.L. Lopalco  Sweden
J. Brotherton  Australia
D. Salisbury  UK
V. Laurent-Ledru  Belgium

Wednesday, May 11

11:00 – 15:00  SPC2 - Best Practices in Publishing Clinical and Public Health Research
Coordinator: E. Franco

Room 1.06

The objectives of this course are:

1) to provide an overview of principles of good scientific practice as applied to research on human subjects (emphasis on cancer research);
2) to discuss elements of scientific reasoning that are used in clinical and public health research and mentorship;
3) to discuss the process of research communication and publishing;
4) to discuss the key features that enhance the quality of a paper and its value to the scientific community.

Instruction will be via interactive lecture to take advantage of students' own experiences as authors; emphasis on issues pertaining to study design, ethics, data analysis, scientific integrity, and strategies of communicating and interpreting results of clinical and public health research.

This course is intended for oncologists, public health practitioners, epidemiologists, and other clinical researchers in the early stages of their careers or those who are switching from clinical or public health practice to research. Public health practitioners and policymakers may also find the contents valuable in understanding the process of scientific research and publishing. Researchers whose mother tongue is not English may find the course particularly helpful in assisting them to navigate the process of preparing, submitting, and revising manuscripts for publication in international biomedical journals.

Note about the instructor:

Dr. Franco has extensive experience as an author, editor, and overseeing the publication process in epidemiology and clinical research in oncology. He has published over 330 scientific articles, 50 chapters, and two books on cancer epidemiology and prevention. He has served as Guest Editor for nine journal supplement issues on the topic of his research (HPV and associated diseases). He has served in the editorial board of the following journals: American Journal of Epidemiology (1993-98); Cancer Detection and Prevention (2001-08), Cancer Epidemiology, Biomarkers & Prevention (1995-); Epidemiology (1993-2009), International Journal of Cancer
(2009-11), Medical and Pediatric Oncology (2000-04), Oral Diseases (2005-), PLoS-Medicine (2004-), Preventive Medicine (2008-) among other journals. He has also served as ad hoc manuscript reviewer for dozens of other biomedical journals.

SATELLITE TRAINING COURSES

Wednesday, May 11

8:30 – 11:30  STC1 - Vulvar diseases course  Room 1.07
Coordinator: J. Bornstein, M. Moyal-Barracco

The satellite course on vulvar disease has been designed for clinicians who currently treat or diagnose women with cervical and vaginal disease. The faculty, all past or present members of the executive council of the International Society for the Study of Vulvovaginal Disease (ISSVD), will discuss current knowledge of vulvar benign and premalignant disease, from various aspects: pathophysiology, clinical features, histological appearance, and treatment. Common and difficult cases will be presented and discussed.

- Introduction  J. Bornstein  Israel
- The dermatoses  M. Moyal  France
- Benign HPV lesions: diagnosis and treatment.  M. Sideri  Italy
- Vulvar pain, difficult cases  J. Bornstein  Israel
- VIN - state of the art  E. Joura  Austria
- Vulvar carcinoma - current treatment. difficult cases  M. Roy  Canada
- Summary and close

Wednesday, May 11

8.00 - 14.00  STC2 - Colposcopy Training Course  Room 1.08
Coordinator: Albert Singer (UK)

This is a 6 hour intensive course conducted by 3 highly experienced colposcopists/oncologists. They will present the most up to date knowledge relating to colposcopy practise as well as of the management of cervix and lower genital tract precancer. There will be lectures as well as a very informal interactive tutorial which will be clinically orientated. Topics will range from the basic (i.e. normal cervix) to advanced (i.e. microinvasion and glandular disease). A CD (PDF form) of all PowerPoint lectures will be given out.

8.00 – 8.10  Welcome  Faculty
8.10 – 8.40  The normal cervix: anatomy and functional changes  A. Singer  UK
8.40 – 9.00  Update on the pathology of cervical precancer  A. Singer  UK
9.00 – 9.05  Questions
9.05 – 9.30  How do we diagnose cervical precancer; cytology , HPV and other methods  W. Prendiville  Ireland
9.30 – 10.30  The abnormal cervix; colposcopy and methods of examination  S. C. Quek  Singapore
- Video case presentations
10.30 – 10.50  Coffee Break
10.50 – 11.30  Microinvasion and glandular cervical disease and other difficult colposcopic examination  S. C. Quek  Singapore
11.30 – 12.15  Treatment of cervical precancer; who, why and how  W. Prendiville  Ireland
12.15 – 12.20  Questions
12.20 – 12.45  Lower genital tract neoplasia: recognition and treatment  A. Singer  UK
12.45 – 13.55  Case presentations ; cytology , colposcopy, pathology and treatment  A. Singer / Faculty
13.55 – 14.00  Summary and close
Segunda Feira, 9 de Maio de 2011
14.00 - 17.00
Secção de Colposcopia - Sessão de HPV

14.00 – 14.30 h  Conferência
- Rui Medeiros, Teresa Rebelo
  • Papilomavírus humano e cancro do colo do útero: Novo conceito de patogenia filogenética e viral  Rui Nobre Jorge

14.30 – 15.50 h  Mesa Redonda – Teste de HPV: O laboratório - José Alberto Moutinho; Margarida Barros

14.30-15.20 h  • Actuais métodos de teste de HPV na prática clínica: Vantagens, limitações e perspectivas futuras  Conceição Saldanha

15.20-15.50 h  • Novos testes moleculares para o diagnóstico das CIN: Futuro ou ilusão?  Rui Medeiros

15.50 – 17.00 h  Mesa Redonda – Teste de HPV: A clínica – João Saraiva; Ana Francisca Jorge

15.50 – 16.20 h  • Teste de HPV e Rastreio do cancro do colo do útero  José Alberto Moutinho

16.20 – 17.00 h  • Como e quando utilizar o teste de HPV na prática clínica diária  Carlos Martins Gomes
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00-14.15 h</td>
<td>Orientação das citologias ASC-US, LSIL e AGC</td>
<td>José Maria Moutinho</td>
</tr>
<tr>
<td>14.15-14.30 h</td>
<td>Tratamento da CIN 1</td>
<td>Rita de Sousa</td>
</tr>
<tr>
<td>14.30-14.45 h</td>
<td>Lesão na margem – o que fazer?</td>
<td>Teresa Paula</td>
</tr>
<tr>
<td>14.45-15.00 h</td>
<td>Seguimento do CIN</td>
<td>João Saraiva</td>
</tr>
<tr>
<td>15.00-15.30 h</td>
<td>Discussão</td>
<td></td>
</tr>
<tr>
<td>15.30 – 16.00 h</td>
<td>Intervalo</td>
<td></td>
</tr>
<tr>
<td>16.00 – 16.20 h</td>
<td>Meios auxiliares de diagnóstico nas doenças vulvares - haverá lugar para a vulvoscopy? -</td>
<td>Martinez de Oliveira</td>
</tr>
<tr>
<td>16.20 – 16.40 h</td>
<td>Tratamento do VIN e dos condilomas vulvares</td>
<td>Teresa Fraga</td>
</tr>
<tr>
<td>16.40 – 17.00 h</td>
<td>Cancro do colo na mulher jovem</td>
<td>Daniel Pereira da Silva</td>
</tr>
<tr>
<td>17.00 – 17.30 h</td>
<td>Discussão</td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>Author</td>
<td>Country</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Frequency of HPV genotypes in women with normal cervical cytology in Paraná state, Brazil</td>
<td>M. Consolaro</td>
<td>Brazil</td>
</tr>
<tr>
<td>Genotypes of human papillomavirus in Sudanese women with cervical pathology</td>
<td>M. Salih</td>
<td>Sudan</td>
</tr>
<tr>
<td>Incidence rates of genital warts in young women and men in France</td>
<td>X. Carcopino</td>
<td>France</td>
</tr>
<tr>
<td>Human papillomavirus genotype distribution in tonsil cancers</td>
<td>D. Riethmüller</td>
<td>France</td>
</tr>
<tr>
<td>Cervical neoplasia in pregnancy - case report and review</td>
<td>L. Correia</td>
<td>Portugal</td>
</tr>
<tr>
<td>Distribution of human papillomavirus genotypes in women with abnormal Pap tests classified according to Bethesda 2001</td>
<td>D. Vrdoljak-Mozetič</td>
<td>Croatia</td>
</tr>
<tr>
<td>Evaluation of predictive value of new sex partners as a predictor of prevalent HPV infection, HR-HPV and prevalence of HPV type 16 in women aged 15-25 years</td>
<td>I. Tsiaousi</td>
<td>Greece</td>
</tr>
<tr>
<td>Genotype specific concordance of genital HPV infections in males and their spouses in Finnish family HPV study</td>
<td>K. Kero</td>
<td>Finland</td>
</tr>
<tr>
<td>Prevalence of genital HPV in women and correlation with other genital infections in Lisbon and vale of Tejo</td>
<td>M. Carvalho</td>
<td>Portugal</td>
</tr>
<tr>
<td>ASC-US: is age a risk factor for the development of CIN?</td>
<td>L. Ferreira</td>
<td>Portugal</td>
</tr>
<tr>
<td>HPV prevalence and other sexually transmitted agents in women</td>
<td>D. Cochichco</td>
<td>Portugal</td>
</tr>
<tr>
<td>The incidence of human papillomavirus (HPV) infection in the Polish army population and its correlation with selected parameters of immunological system</td>
<td>A. J. Jakimiuk</td>
<td>Poland</td>
</tr>
<tr>
<td>Difference of HPV genotyping in cervical precancer and cancer</td>
<td>H. S. Choi</td>
<td>Korea</td>
</tr>
<tr>
<td>Human papillomavirus disease burden in Portugal</td>
<td>R. Santana</td>
<td>Portugal</td>
</tr>
<tr>
<td>ASC-H: treatment and recurrence post-loop electrosurgical excision procedure (LEEP)</td>
<td>M. Silva</td>
<td>Brazil</td>
</tr>
<tr>
<td>HPV prevalence among clinically healthy Italian male population and genotype concordance between sexual partners</td>
<td>A. Vocaturo</td>
<td>Italy</td>
</tr>
<tr>
<td>The cost burden of genital warts in the UK</td>
<td>S. Caroll</td>
<td>UK</td>
</tr>
</tbody>
</table>
Screening

- Primary screening for cervical cancer in Cameroon: self- vs clinician-collected specimens for HPV detection  
  I. Navarria Switzerland
- Analysis of four-year cervical cancer screening program with visual inspection as primary screening method in a south-west rural area in China  
  R. Li China

HPV testing

- Type specific detection of high-risk human papillomavirus in self-obtained cervicovaginal samples applied to FTA elute cartridges  
  I. Gustavsson Sweden
- Comparison of five CE/IVD labeled HPV DNA genotyping assays  
  M. Bozic Austria
- Performance of cobas 4800 HPV test compared with the Hybrid Capture 2  
  N. Verdasca Portugal
- Improved procedures to recover HPV mRNA from BD SurePath preservative fluid and enhance detection with the APTIMA® HPV assay  
  J. Dockter USA
- Clinical performance of several HPV assays in women referred for HPV testing  
  C. Sousa Portugal
- Evaluation of the Abbott RealTime high risk HPV test for the detection and identification of human papillomaviruses in archival cervical cancer specimens  
  B. Kocjan Slovenia
- Quantification and genotyping of human papillomavirus by Real-Time PCR and HPV DNA chip in cervical samples  
  Y. S. Kang Korea
- A novel, automated DNA extraction method from cervical SurePath® specimens  
  K. Lindebaum Germany
- Comparative study of HPV genotypes and clinical diagnosis of carcinoma of the oral cavity through reverse hybridization.  
  A. Fernandes Venezuela
- Comparison of the new cobas® 4800 HPV test and a consensus HPV PCR/sequencing assay completed with INNO-LiPA genotyping  
  M. Coste-Burel France
- Development of an HPV genotyping assay capable of specifically detecting HPV 16, 18, and 45  
  H. Thai USA
- Prevalence of high-risk human papillomavirus in high grade lesion of cervix  
  S. Swangvaree Thailand

Molecular markers

- HPV infection and TP53 codon 72 polymorphism in cervical carcinoma patients from Serbia  
  E. Malisic Serbia
• Correlation between immunohistochemistry of HPV L1 capsid protein and behavior of low-grade cervical cytology in Korean women
  J. S. Park Korea
• A case-control study of the Killer-cell Immunoglobulin-like Receptor (KIR) genes and genotypes in relation to HPV-mediated cervical neoplasia in Korean women
  E. Y. Ki Korea
• Clinical and molecular characterization of small vulvar cancer of the anterior fourchette
  M. Hampl Germany
• Profiling of low abundant plasma proteome of cervical cancer by two dimensional liquid phase chromatography
  X. Guo China
• Role of p16\textsuperscript{ink4a}, and hTERT in early detection of cervix cancer
  D. Stanescu Romania
• Evaluation of MCM-2 and p16 in cervical cancer tissue micro-array (TMA)
  A. Nicol Brazil
• P16\textsuperscript{ink4a}/Ki-67 dual stain cytology in samples from Kenyan women
  M. Reuschenbach Germany
• Negative correlation between dynamin 2 expression and degree of cervical intraepithelial neoplasia: a comparison with Ki-67 expression and detection of HPV types
  D. S. Bae Korea
• Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in cervical carcinoma
  B. G. Kim Korea

Diagnosis & management

• Merkel cell carcinoma developed in a patient with epidermodysplasia verruciformis
  T. Ishiji Japan
• CIN 3 treatment and its consequences on further pregnancies
  G. Dinca Romania
• Cervical intraepithelial neoplasia in young women
  A. Almeida Portugal
• Effectiveness of conization on treating CIN lesions – 5 years retrospective study at the Hospital of Faro - EPE (Portugal)
  V. Ribeiro Portugal
• Women under 30 with high grade squamous intraepithelial lesions – 2007 to 2010: Our experience
  O. Figueiredo Portugal
• HSIL: correlation between cytology, colposcopy and histology
  C. Oliveira Portugal
• Optoelectronic scanner truscreen in diagnostics of cervical squamous intraepithelial lesions
  T. Bebneva Russia
• AGC – retrospective study of the last 9 years
  I. Ramilo Portugal
• Vulvar intraepithelial neoplasia – a diagnostic challenge
  V. Stepanić Croatia
<table>
<thead>
<tr>
<th>Title</th>
<th>Author</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>A pilot study to investigate the treatment of cervical human papillomavirus infection with zinc-citrate compound (CIZAR®)</td>
<td>T. C. Park</td>
<td>Korea</td>
</tr>
<tr>
<td>Cervical cancer in young female</td>
<td>A. F. Jorge</td>
<td>Portugal</td>
</tr>
<tr>
<td>Study on the clinical strategy of cervical lesion in gestation period</td>
<td>Y. Zhao</td>
<td>China</td>
</tr>
<tr>
<td>Loop excision for high-grade squamous intraepithelial lesion on cytology: correlation with histologic findings</td>
<td>P. Nogara</td>
<td>Brazil</td>
</tr>
<tr>
<td>Difference of clinical background by HPV genotypes among the patients undergone with therapeutic conization</td>
<td>M. Nagata</td>
<td>Japan</td>
</tr>
<tr>
<td>An 18 year old girl with a clear cell adenocarcinoma of the cervix: a case report</td>
<td>S. Barreto</td>
<td>Portugal</td>
</tr>
<tr>
<td>Health and economic impact of a quadrivalent (6/11/16/18) HPV vaccination programme on the burden of genital warts in the UK</td>
<td>V. Remy</td>
<td>France</td>
</tr>
<tr>
<td>Clinical significance of atypical glandular cells on cervical cytology. The experience of university hospitals of Coimbra</td>
<td>S. Campos</td>
<td>Portugal</td>
</tr>
<tr>
<td>HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB-IIA cervical cancer undergoing radical hysterectomy</td>
<td>S. M. Kim</td>
<td>Korea</td>
</tr>
<tr>
<td>The significance of HPV genotype in patients with early cervical cancer who undergoing radical hysterectomy</td>
<td>J. H. Kim</td>
<td>Korea</td>
</tr>
<tr>
<td>The association between HPV viral load and clinicopathologic risk factors in early-stage cervical cancer</td>
<td>J. H. Nam</td>
<td>Korea</td>
</tr>
<tr>
<td>Reconisation or repeated hpv test?</td>
<td>R. Koiss</td>
<td>Hungary</td>
</tr>
</tbody>
</table>

**Programs, knowledge, awareness and information**

<table>
<thead>
<tr>
<th>Title</th>
<th>Author</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV prophylactic vaccine coverage in France: results of a survey among high school and university students in Marseilles’ area</td>
<td>X. Carcopino</td>
<td>France</td>
</tr>
<tr>
<td>Reasons for HPV vaccine non-compliance in women aged between 18 to 26 years old, according to an HPV vaccination recording network in Athens</td>
<td>E. Deligeoroglou</td>
<td>Greece</td>
</tr>
</tbody>
</table>
• Factors associated with attendance to cervical screening in an organized screening program
  B. T. Hansen  Norway

• Evaluation of HPV vaccine coverage across different age-groups from a HPV vaccination recording network in Athens
  P. Drakakis  Greece

• Cervical cancer in Croatia: the importance of public education campaigns for cervical cancer prevention
  D. Eljuga  Croatia

**Immunization**

• Neutralisation of non-vaccine HPV genotypes by sera from vaccinated girls
  E. Draper  UK